Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.
February 27, 2024 | 7:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Esperion Therapeutics with an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst like Serge Belanger could instill confidence among investors, potentially leading to a positive short-term impact on ESPR's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100